Latest news for Mesoblast (OTC:MEOBF) Stock

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Cannabis

News

Penny Stocks

Psychedelics

Small Cap

Markets

AVTX

HALO

MEOBF

MNMD

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

MindMed Appoints Schond L. Greenway As CFO

Mesoblast Ltd

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited is set to join the Nasdaq Biotechnology Index, marking a significant milestone...

Mesoblast Limited Joins Prestigious Nasdaq Biotechnology Index

Mesoblast (MESO) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI) as part of the annual reconstitution of the 2024 Nasdaq in...

Mesoblast to be added to Nasdaq Biotechnology Index

The company states: "Mesoblast (MESO) announced the FDA approved Ryoncil, remestemcel-L, as the first mesenchymal stromal cell, MSC, therapy in the...

Mesoblast RYONCIL becomes first FDA-approved mesenchymal stromal cell therapy

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has received FDA approval for Ryoncil, making it the first mesenchymal stromal...

Mesoblast's Ryoncil: A Breakthrough in Pediatric Therapy

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has received FDA approval for RYONCIL, the first mesenchymal stromal cell ther...

FDA Approval Boosts Mesoblast's Market Position

Piper Sandler raised the firm's price target on Mesoblast (MESO) to $15 from $11 and keeps an Overweight rating on the shares after the FDA approve...

Mesoblast price target raised to $15 from $11 at Piper Sandler

Maxim raised the firm's price target on Mesoblast (MESO) to $30 from $18 and keeps a Buy rating on the shares after the FDA approved Ryoncil as the...

Mesoblast price target raised to $30 from $18 at Maxim

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited's Director, Dr. Eric Rose, has significantly increased his stake in the compan...

Mesoblast Director Increases Stake with Major Share Acquisition

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has announced the quotation of over five million new ordinary shares on the Au...

Mesoblast Limited Expands Equity with New Share Quotation

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Mesoblast (MESO – Research Report) yesterday and set a price target of $15.00. The...

Piper Sandler Reaffirms Their Buy Rating on Mesoblast (MESO)

MESO

Mesoblast

Mind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.

&ldquo;We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech capital markets, which was a key attribute we sought in identifying a CFO,&rdquo; stated Robert Barrow, CEO and director of MindMed. &ldquo;Schond is joining MindMed at an exciting point in our growth, with numerous near-term milestones ahead across our pipeline. I look forward to working closely with him to advance our mission of becoming a global leader in the development of innovative therapies for brain health disorders.&rdquo;

Greenway joins MindMed after serving as CFO of Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>), a precision medicine clinical stage bio-pharmaceutical company. He previously served as VP of investor relations at Mesoblast (OTCPK:MEOBF), an allogeneic cellular medicines company. He served in a similar role at Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) and in various roles at investment banking firms Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) and Barclays Capital, predominantly focused on healthcare and technology.

Photo: Courtesy of <a href="https://unsplash.com/@cytonn_photography?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Cytonn Photography</a> on <a href="https://unsplash.com/s/photos/handshake?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Related News

<a href="https://www.benzinga.com/general/biotech/22/05/27303544/mindmed-reports-promising-results-for-non-hallucinogenic-ibogaine-congener-substance" target="_blank">MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance</a>

<a href="https://www.benzinga.com/markets/cannabis/22/05/27227735/mindmed-reports-financial-results-for-q1-with-lower-cash-balance-compared-to-december-last-year" target="_blank">MindMed Reports Financial Results For Q1, With Lower Cash Balance Compared To December Last Year</a>

<a href="https://www.benzinga.com/general/biotech/22/05/27168268/can-lsd-treat-anxiety-this-new-clinical-topline-data-by-mindmed-is-very-promising" target="_blank">Can LSD Treat Anxiety? MindMed&#39;s New Topline Data Show Promise, Here&#39;s The Research</a>

&nbsp;

Comments

Mesoblast

News

Latest news for Mesoblast (OTC:MEOBF) Stock

Monday, May 23, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga